Skip to main content

Table 2 Univariate analysis by chi-square test or Fisher’s exact test

From: Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors

Risk factor

Odds ratio

95 % C.I.

P-value

CKD risk factors

   

 Smoking

0.7

0.19–2.53

0.59

 Hypertension

2.3

0.79–6.66

0.12

 Dyslipidemia

2.25

0.70–7.20

0.17

 Use of NSAIDs

3.56

1.11–11.39

0.04

 Obesity

0.51

0.10–2.50

0.4

 Diabetes mellitus

0.91

0.17–4.70

0.91

 Hyperuricemia

1.05

0.20–5.57

0.95

 Urinary tract stone

-

 

0.12

 Age ≥70

0.5

0.06–4.31

0.52

 Cardiac disease

6

1.21–29.87

0.04

 Hematuria

-

 

0.29

 Cerebrovascular disease

-

 

0.29

 Autoimmune disease

4

0.52–30.61

0.15

 Proteinuria

-

 

0.6

 Infectious disease

-

 

-

 Past history of ARF

-

 

-

 Pt. with CKD risk

-

 

0.29

 Pt. without CKD risk

-

 

0.29

No. of CKD risk factors

   

 ≤2

1

  

 3

1.54

0.39–5.96

0.72

 4

1.5

0.34–6.7

0.69

 ≥5

5

0.85–29.39

0.09

Other risk factors

   

 PS ≥1

0.68

0.23–2.01

0.48

 Alb <3.5 g/dL

0.69

0.24–1.97

0.49

 Female

1.43

0.44–4.69

0.56

Anticancer drugs

   

 Vinorelbine

1

0.35–3.25

0.9

 Etoposide

2.44

0.70–8.49

0.15

 Docetaxel

0.7

0.14–3.53

0.66

 Pemetrexed

0.33

0.04–2.76

0.29

 Gemcitabine

3.94

0.51–30.14

0.16

 S-1

3.94

0.51–30.14

0.16

  1. AKI acute kidney injury, CKD chronic kidney disease, NSAID non-steroidal anti-inflammatory drug, ARF acute renal failure, PS performance status, C.I. confidential interval
  2. Bold P-values are significant at the 0.05 level